Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.84 USD | -1.46% | +2.29% | +63.44% |
May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.44% | 1.69B | |
+36.71% | 50.93B | |
-0.72% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+12.28% | 26.02B | |
-22.73% | 18.9B | |
+7.93% | 13.21B | |
+24.63% | 12.17B | |
+29.21% | 12.16B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- JPMorgan Adjusts Edgewise Therapeutics' Price Target to $32 from $33, Maintains Overweight Rating